A Comparison of Three Extrusion Systems (Part II) - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Comparison of Three Extrusion Systems (Part II)
The authors compare three systems of single-screw extrusion using binary formulations for their suitability for producing pellets of various formulations and under various spheronization conditions.


Pharmaceutical Technology
Volume 35, Issue 6, pp. 56-61

References

1. A. Désiré et al., Pharm. Technol. 35 (1), 56–65 (2011).

2. C. Lustig-Gustafsson et al., Eur. J. Pharm. Sci. 8 (2), 147–152 (1999).

3. G. Tomer, F.Podczeck, and J.M. Newton, Int. J. Pharm. 217 (1–2), 237–248 (2001).

4. G. Tomer, F. Podczeck, and J.M. Newton, Int. J. Pharm. 231 (1), 248–257 (2002).

5. J.J. Sousa et al., Int. J. Pharm. 232 (1–2), 91–106 (2002).

6. J. Chatchawalsaisin, F. Podczeck, and J.M. Newton, Eur J Pharm Sci. 24 (1), 35–48 (2005).

7. D. Lutchman, C.M. Dangor, and D. Perumal, J. Microencapsul. 22 (6), 643–659 (2005).

8. F.O. Costa, A.A.C.C. Pais, and J.J.S., Int. J. Pharm. 270 (1–2), 9–19 (2004).

9. G.A. Hileman et al., Int. J. Pharm. 100 (1–3), 71–79 (1993).

10. L. Baert and G.R.B. Down, Int. J. Pharm. 107 (3), 219–222 (1994).

11. L. Alvarez et al., Eur. J. Pharm. Biopharm. 55 (3), 291–295 (2003).

12. R. Gandhi et al., Pharm. Technol. 29 (2). 68–86 (2005).

13. L. Rahman et al., STP Pharm. Sci. 1 (5), 294–299 (1991).

14. E. Nürnberg, and J. Wunderlich, Pharm. Technol. Eur. 11 (3), 30-34 (1999).

15. S. Galland, T. Ruiz, and M. Delalonde, Int. J. Pharm. 337 (1–2), 239–245 (2007).

16. S. Galland, T. Ruiz, and M. Delalonde, Powder Technol. 190 (1–2), 48–52 (2009).

17. J.F. Pinto and C.N. Abreu, Drug. Dev. Ind. Pharm. 32 (9), 1067–1078 (2006).

18. L. Hellén, J. Yliruusi, and E. Kristoffersson, Int. J. Pharm. 96 (1–3), 197–204 (1993).

19. L. Hellén, J. Yliruusi, and E. Kristoffersson, Int. J. Pharm. 96 (1–3), 205–216 (1993).

20. L. Hellén, J. Yliruusi, and E. Kristoffersson, Int. J. Pharm. 96 (1–3), 217–223 (1993).

21. A.M. Juppo et al., Eur. J. Pharm. Biopharm. 44 (2), 205–214 (1997).

22. V.R. Sinha et al., AAPSPharmSciTech, 8 (1), E1–E5 (2007).

23. S. Galland et al., Powder Technol. 157 (1–3), 156–162 (2005).

24. D. Sonaglio et al., Int. J. Pharm. 115 (1), 53–60 (1995).

25. E.I. Hamedelniel, J.Bajdik, and K.Pintye-Hódi, Chemical Engineering and Processing: Process Intensification 49 (1), 120–124 (2010).

26. A. Häring, K. Krejcova, and M. Rabiskova, Farm. Vestn. 54 (special issue), 437–438 (2003).

27. L. Baert et al., Int. J. Pharm. 86 (2–3), 187–192 (1992).

28. L. Baert et al., Int. J. Pharm. 99 (1), 7–12. (1993).

29. C. Schmidt, H. Lindner, and P. Kleinebudde, Eur. J. Pharm. Biopharm. 44 (2), 169–176 (1997).

30. K. Thoma and I. Ziegler, Drug Dev. Ind. Pharm. 24 (5), 401–411 (1998).

31. K. Thoma, and I. Ziegler, Drug Dev. Ind. Pharm. 24 (5), 413–422 (1998).

32. D. Sonaglio, B. Bataille, and M. Jacob, Pharm. Acta Helv. 72 (2), 69–74 (1997).

33. C. Schmidt, and P. Kleinebudde, Eur. J. Pharm. Biopharm. 45 (2), 173–179 (1998).

34. J.M. Newton, S.R. Chapman, and R.C. Rowe, Int. J. Pharm. 120 (1), 101–109 (1995).

35. D. Sonaglio et al., Pharmazie 52 (2), 129–134 (1997).

36. P. Costa and J.M. Sousa Lobo, Eur. J. Pharm. Sci. 13 (2), 123–133 (2001).

37. E. Jerwanska et al., Int. J. Pharm. 121 (1), 65–71 (1995).

38. P. Kleinebudde and H. Lindner, Int. J. Pharm. 94 (1–3), 49–58 (1993).

39. A.B. Bashaiwoldu, F. Podczeck and J.M. Newton, Eur. J. Pharm. Sci. 21 (2–3), 119–129 (2004).

40. B. Song, S.L. Rough, and D.I. Wilson, Int. J. Pharm. 332 (1–2), 38–44 (2007).

41. J.P. Perez and M. Rabiskova, Int. J. Pharm. 242 (1–2), 349–351 (2002).

42. J.J. Sousa et al., Int. J. Pharm. 144 (2), 159–169 (1996).

43. J. Berggren and G. Alderborn, Int. J. Pharm. 219 (1–2), 113–126 (2001).

44. P. Kleinebudde, Int. J. Pharm. 109 (3), 209–219 (1994).

45. P. Kleinebudde, Int. J. Pharm. 109 (3), 221–227 (1994).

46. B. Bataille, K. Ligarski, and M. Jacob, Pharm. Acta Helv. 65 (12), 334–337 (1990).

47. K. Ligarski et al., STP Pharma Sci. 1 (4), 256–261 (1991).

48. B. Bataille et al., Drug Dev. Ind. Pharm. 19 (6), 653–671 (1993).

49. K. Umprayn, P. Chitropas, and S. Amarekajorn, Drug Dev. Ind. Pharm. 25 (1), 45–61 (1999).

Citation: When referring to this article, please cite it as "Amelie Desire, Bruno Paillard, Joel Bougaret, Michel Baron, Guy Couarraze, "A Comparison of Three Extrusion Systems (Part II)," Pharmaceutical Technology 35 (6) 56-61(2011)."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here